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Abstract
Cutaneous wound healing is a normal physiological process and comprises different phases. Among these phases,
angiogenesis or new blood vessel formation in wound tissue plays an important role. Skin is richly supplied by sympathetic
nerves and evidences indicate the significant role of the sympathetic nervous system in cutaneous wound healing.
Dopamine (DA) is an important catecholamine neurotransmitter released by the sympathetic nerve endings and recent
studies have demonstrated the potent anti-angiogenic action of DA, which is mediated through its D2 DA receptors. We
therefore postulate that this endogenous catecholamine neurotransmitter may have a role in the neovascularization of
dermal wound tissues and subsequently in the process of wound healing. In the present study, the therapeutic efficacy of
D2 DA receptor antagonist has been investigated for faster wound healing in a murine model of full thickness dermal
wound. Our results indicate that treatment with specific D2 DA receptor antagonist significantly expedites the process of full
thickness normal dermal wound healing in mice by inducing angiogenesis in wound tissues. The underlined mechanisms
have been attributed to the up-regulation of homeobox transcription factor HoxD3 and its target a5b1 integrin, which play
a pivotal role in wound angiogenesis. Since D2 DA receptor antagonists are already in clinical use for other disorders, these
results have significant translational value from the bench to the bedside for efficient wound management along with other
conventional treatment modalities.
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Introduction
Angiogenesis is an important process of new blood vessel
formation that occurs in the body, both in health and in diseases.
This process is further controlled by precise balance between pro-
and anti-angiogenic factors in different normal physiological
conditions like wound healing. Shifts in the finely tuned equilibrium
between angiogenic stimulators and inhibitors that regulate
angiogenesis lead to either excessive or insufficient angiogenesis,
thereby causing many angiogenesis-dependent diseases, including
cancer and other diseases such as atherosclerosis, age-related
macular degeneration and rheumatoid arthritis [1].
Reports from our laboratory have shown that peripheral
endogenous neurotransmitter dopamine by acting through its D2
DA receptors present in the endothelial cells (ECs) can significantly
suppress vascular permeability factor/vascular endothelial growth
factor (VEGF/VPF) induced tumor angiogenesis by inhibiting
phosphorylation of vascular endothelial growth factor receptor 2
(VEGFR2), the principal VEGF receptor mediating the angio-
genic effects of VEGF, focal adhesion kinase (FAK) and mitogen-
activated protein kinase (MAPK) [2–5]. Moreover, DA can also
suppress neovascularization in tumors by inhibiting mobilization
of endothelial progenitor cells (EPCs) from the bone marrow to
tumor vascular bed via DA D2 receptor-mediated inhibition of
matrix metalloproteinase 9 (MMP-9) synthesis and ERK-1/ERK-
2 signaling pathways in these cells [6]. These studies have
conclusively demonstrated DA as a novel endogenous inhibitor of
angiogenesis in malignant tumors.
In contrast to tumor angiogenesis, neovascularization in wound
tissue is a normal physiological process essential for the
regeneration of damaged tissues by formation of new blood vessels
to maintain tissue viability, provide nutrients, and oxygen supply
to the growing tissues, thereby aiding in the formation of
provisional wound matrix or granulation tissue [7–11]. However,
the regulatory role of DA, if any, in this process of physiological
angiogenesis during wound tissue repair is not yet known. Dermal
tissues are richly innervated by sympathetic nerves and recent
reports indicate important role of these nerves in cutaneous wound
healing [12–18]. Furthermore, dopamine is an important
neurotransmitter in the sympathetic nervous system and DA has
been established as an endogenous inhibitor of angiogenesis [2–
6,12–14]. Because DA mediates its anti-angiogenic effects by
acting through its D2 receptors present in endothelial cells [2], we
therefore investigated whether treatment with D2 DA receptor
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the process of healing in a murine model of full thickness dermal
wound.
Results
Treatment with specific D2 DA receptor antagonist
accelerates dermal wound healing in mice
As angiogenesis is critical to successful wound repair and DA is
an endogenous inhibitor of angiogenesis [2–6], the therapeutic
efficacy of specific D2 DA receptor antagonist eticlopride in vivo
was evaluated for faster wound healing in a murine model of full
thickness dermal wound. Our results indicated that treatment with
eticlopride (10 mg/kg/4 day i.p.), significantly improved the rate
of wound healing in normal Swiss mice with resurfacing of intact,
new skin occurring by 9 days (Fig. 1A), whereas the full thickness
dermal wounds on the back of vehicle treated control Swiss mice
required 14 days for complete closure. These results thus indicated
that treatment with eticlopride significantly sped up (p,0.05) the
healing process in wound bearing normal Swiss mice than vehicle
treated control mice. The total surface area of the wound also
decreased significantly after completion of the treatment on day 4
in comparison to saline treated controls (Fig. 1B). On day 5, the
percent of wound closure was 53.4% in treated groups versus
25.5% in control groups, whereas it was 78.3% in treated versus
38.2% in controls on day 7 (Fig. 1B). Also the mean wound size of
the treated group was always significantly smaller at all time points
(p,0.05) than untreated groups from day 2 until the day of
complete healing (Fig. 1B). Like eticlopride, treatment with
domperidone, another D2 DA receptor specific antagonist also
significantly accelerated the rate of wound healing in murine
model of full thickness dermal wounds (data not shown). However,
no significant changes were observed in the rate of wound healing
when other dopamine receptor antagonists (D1,D 3,D 4 and D5)
were used (data not shown). This data confirmed that the action of
DA was specific and was through its D2 receptors.
Significantly increased angiogenesis in wound bed of
specific D2 DA receptor antagonist treated group than
vehicle treated controls
As angiogenesis plays a pivotal role in wound healing and
endogenous DA by acting through its D2 receptors acts as a potent
inhibitor of angiogenesis, we therefore investigated whether the
eticlopride mediated faster wound healing was associated with
significantly increased angiogenesis in wound tissues. At day 5
after the completion of 4 day treatment schedule of eticlopride, the
number of microvessels was significantly higher (p,0.05) in
wound beds of eticlopride treated mice than vehicle treated
controls (Fig. 1C and 1D). This significantly enhanced angiogen-
esis in wound tissues also correlated well with the faster wound
healing in eticlopride treated mice. Microvessel density was
calculated by counting the number of CD31 positive cells after
performing immunohistochemistry of frozen wound tissue sections
[6].
Increased expression of HoxD3, a regulator of
angiogenesis and its target gene a5b1 in wound bed
following treatment with specific D2 DA receptor
antagonist
Among the different genes regulating the process of angiogen-
esis, HoxD3, a homeobox transcription factor, plays a critical role
in regulating neovascularization in wounds [19–21]. HoxD3 is a
member of the homeobox (Hox) family of master transcription
factors that are expressed during normal embryogenesis, skin
development and during fetal wound healing [22–24]. Further-
more, HoxD3 can modulate the expression of number of genes,
among which a5b1 integrin is well associated with angiogenesis
[20,25,26]. Therefore, the mechanism of D2 dopamine receptor
antagonist eticlopride mediated increased angiogenesis in wound
tissue as observed in the present study was explored by
determining the expression of HoxD3 and a5b1 integrin in
wound bed.
Our results indicate that eticlopride treatment, which acceler-
ated wound tissue neovascularization had significant positive
regulatory effect on the expression of this master transcription
factor (HoxD3) in wound tissue as evident from immunoblot
analysis at day 5 post wounding (24 hours after completion of 4
day schedule of eticlopride treatment) (Fig. 2A and 2B). In
addition, on day 5, following completion of eticlopride treatment,
the expression of a5b1 integrin, target gene of the transcription
factor HoxD3 was also significantly up-regulated in these wound
tissues as determined by immunohistochemistry (Fig. 2C).
DA inhibits the expression of HoxD3 and its target genes
a5 and b1 integrins in HUVEC
Endothelial cells are principal cellular components of the blood
vessels and proliferation and migration of these cells play a central
role in angiogenesis [1,7]. Our in vivo results indicated increased
expressions of HoxD3 transcription factor along with a5b1
integrin in wound tissues following eticlopride treatment, which
in turn was associated with increased angiogenesis in wound bed.
It was also reported that in endothelial cells, up-regulation of
HoxD3 and its target gene a5b1 integrin were closely associated
with angiogenic processes like proliferation and migration of these
cells following exposure to growth factors [20,25]. Among the
different growth factors that regulate wound angiogenesis, VEGF
plays a critical role in inducing angiogenesis in wound tissues.
Furthermore VEGF is thought to regulate different processes like
vascular permeability, migration and proliferation of endothelial
cells during wound repair [27–29]. Therefore, experiments were
designed in vitro to examine the direct effects of DA on the
expressions of HoxD3 and a5b1 integrin in endothelial cells
following treatment with VEGF. Since dermal tissues are richly
supplied with sympathetic nerves and because 1 mMo fD Ai s
present in the extracellular fluid surrounding neural synapses [30],
we therefore used this concentration of DA for our in vitro
experiments. HUVEC were especially selected because these cells
express both HoxD3 and D2 DA receptors [2,20,31]. It is also to
be noted here that murine dermal angiogenic endothelial cells
express D2 DA receptors [2]. Immunoblot of HUVEC showed
presence of D2 DA receptors in these cells (Fig. 3A). This was
further confirmed by flow cytometry analysis which revealed that
over 81% cells of the total HUVEC population express D2
dopamine receptors on their surfaces (Fig. 3B).
Although serum starved HUVEC did not show any expression
of HoxD3, significant expressions of both HoxD3 and its target
genes a5 and b1 integrins were observed 8 hrs after treatment with
VEGF at a concentration of 10ng/ml. In contrast, when exposed
to DA (1 mM), the expressions of both HoxD3 and its target genes
a5 and b1 integrins were significantly down-regulated. However,
pre-treatment with specific D2 DA receptor antagonist eticlopride
abrogated the effects of DA (Fig. 4A-4C) thus further indicating
that inhibition of this growth factor induced HoxD3 expression by
DA was mediated through its D2 receptors. These results
corroborate with our in vivo experiments where eticlopride
treatment was associated with increased expressions of HoxD3
and a5b1 integrin along with stimulation of angiogenesis in wound
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25215Figure 2. Effect of eticlopride treatment on expression of HoxD3 and its target a5b1 integrin in cutaneous wound tissue of mice. (A)
Immunoprecipitation followed by immunoblot analysis of HoxD3 expression in wound tissues of both eticlopride and saline treated wound bearing
mice at day 5 post wounding. The immunoblot analysis shows significantly higher expression of HoxD3 protein in wound tissues of eticlopride
treated mice than vehicle treated controls at 5
th day after creation of wounds. (B) The bar graphs represent the density of each HoxD3 protein band
relative to the IgG expression as quantified by ImageJ (NIH), *, P,0.05. (C) Immunohistochemical analysis of the expression of a5b1 integrin in
cutaneous wound tissues of both control and eticlopride treated mice at day 5 post wounding. Frozen sections were immunostained with anti-a5b1
integrin antibodies followed by biotin conjugated secondary antibodies. The sections were stained using ABC staining kit and Nova-Red substrate
solution to develop color. Significantly more areas of wound bed show positive staining (reddish brown color) for a5b1 integrin following eticlopride
treatment. Original magnifications, x 100. Results are representative of six separate experiments each yielding similar results.
doi:10.1371/journal.pone.0025215.g002
Figure 1. Effect of eticlopride treatment on macroscopic aspect of wound closure and formation of new blood vessels in wound
bed. (A) The treatment with eticlopride, a specific D2 dopamine receptor antagonist; 10 mg/kg/4 days/i.p. significantly accelerated the rate of wound
healing with resurfacing occurring by 9 days whereas complete wound closure in controls occurred on day 14. The control group received similar
volume of normal saline only. (B) Wound closure analysis. In treatment group of mice eticlopride significantly accelerated wound closure compared
to vehicle treated control (each group, n=6; *, P,0.05). Time to wound closure was defined as the time until the re-epithelialization process was
complete and the wound bed was filled with new tissues. The percentage of wound closure was calculated as: (area of original wound 2 area of
actual wound) x100/area of original wound and were measured by analyzing images using an image analysis program (ImageJ, NIH). (C)
Immunohistochemical staining of CD31, a specific endothelial cell surface marker to enumerate the number of microvessels. The figure shows
significantly greater number of microvessels (reddish brown in color) in wound tissue sections of eticlopride treated mice in comparison to vehicle
treated controls. Original magnifications,6100. (D) Graphical representation shows significantly higher number of microvessels in eticlopride treated
groups when compared to vehicle treated controls at day 5, 24 hours after completion of treatment schedule. Microvessel density was measured by
counting the number of microvessels in 10 randomly chosen high power microscopic fields within the sections,*, P,0.05). Results are representative
of six separate experiments each yielding similar results.
doi:10.1371/journal.pone.0025215.g001
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25215Figure 3. D2 Dopamine receptors are present on the surface of human umbilical vein endothelial cells. (A) Immunoblot shows presence
of D2 dopamine receptors in HUVEC. (B) Flow cytometric analysis of D2 dopamine Receptors in HUVEC. Over 81% cells of the total HUVEC population
express D2 dopamine receptors on their surfaces as evident from the lower right quadrant.
doi:10.1371/journal.pone.0025215.g003
Figure 4. Dopamine through its D2 receptors can significantly downregulate VEGF induced expressions of HoxD3 and its target
genes a5 and b1 integrins in HUVEC. (A, B and C) Western blot analysis of the effect of dopamine on VEGF induced expressions of HoxD3 and
its target genes a5 and b1 integrins in HUVEC. Lane 1: Serum starved Human Umbilical Vein Endothelial Cells show no expression of HoxD3. However
expression of both a5 and b1 integrins was observed. Lane 2: Cells stimulated with VEGF (10 ng/ml) show significant expression of HoxD3 and both
the integrins after 8 hours of stimulation. Lane 3: Cells pretreated with 1 mM dopamine (concentration of DA found in synaptic clefts) 5 minutes
before being exposed to VEGF (10 ng/ml) show significantly down-regulated VEGF induced expression of HoxD3 and both a5 and b1 integrins
compared with VEGF treated controls. Lane 4: Cells treated with 100 mM eticlopride followed by dopamine and VEGF. Pre-treatment with eticlopride
abrogated dopamine-induced down-regulation of HoxD3 and its target a5 and b1 integrin expression in HUVEC. b-actin was used as loading controls.
Results are representative of six separate experiments each yielding similar results. (D, E and F) The bar graphs represent the density of each protein
band relative to the b-actin expression. These have been quantified by ImageJ (NIH), *, P,0.05.
doi:10.1371/journal.pone.0025215.g004
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endogenous DA acts as a negative regulator of wound angiogenesis
and treatment with D2 DA receptor specific antagonist abrogates
this negative effect of DA as increased angiogenesis was observed
in the wound tissues of eticlopride treated animals.
Discussion
Skin is richly innervated by sympathetic nerves and there are
now several reports which indicate that these nerves can regulate
healing of cutaneous wounds [12,15–18]. It is also now well
established that angiogenesis plays a central role in cutaneous
wound tissue repair by influencing different facets of wound
healing [9–11]. DA is one of the catecholamine neurotransmitters
released from the sympathetic nerve endings [12–14] and we had
earlier demonstrated DA to be an endogenous inhibitor of tumor
angiogenesis [2–6].
Our present results have shown that treatment with eticlopride,
a specific D2 DA receptor antagonist significantly accelerates
angiogenesis in wound tissues, thereby inducing faster healing of
full thickness dermal wounds in normal mice. As angiogenesis
induces rapid and successful wound healing [19,27,32], therefore,
it can be suggested that eticlopride by augmenting neovascular-
ization induces an ambient microenvironment in the wound bed
favorable for implementing the other major steps required for
wound healing.
Moreover recent studies have demonstrated the important roles
of HoxD3, a member of homeobox (Hox) family of transcription
factors, in wound angiogenesis [19–21]. The expression of HoxD3
is up-regulated in normal wound tissues, whereas its expression is
decreased in poorly healing wounds of genetically diabetic (db/db)
mice [19–21]. Interestingly, restoration of HoxD3 by gene transfer
has been reported to accelerate diabetic wound healing by
modulating the expressions of number of genes associated with
wound angiogenesis [19–21,25–26]. Therefore, to understand the
molecular basis of this increased angiogenesis in wound bed
following D2 DA receptor antagonist treatment, the expressions of
HoxD3 and its principal target gene a5b1 integrin in wound
tissues were examined. In vivo results revealed a direct correlation
between significant up-regulation of HoxD3 and its target gene
a5b1 integrin in wound tissues and wound neovascularization
following eticlopride treatment. This present data also corrobo-
rates well with the previous observations by Boudreau and Varner
demonstrating the regulatory role of the transcription factor
HoxD3 in the expression of a5b1, an important initiator of
angiogenesis [25]. It has been reported that HoxD3 binds directly
to the promoters of integrin a and b subunits and induces their
expressions in endothelial cells during angiogenesis, whereas knock
down of HoxD3 by antisense treatment, significantly down-
regulates the expression of a5b1 in endothelial cells [25]. As the
results of our in vivo experiments had indicated increased
expression of HoxD3 and its target a5b1 integrin in wound beds
of mice following eticlopride treatment, further experiments were
designed in vitro to confirm the in vivo results. Recent studies have
indicated that growth factors can induce HoxD3 expression in
endothelial cells, which in turn is associated with increased
proliferation and migration of endothelial cells, a prerequisite for
formation of new blood vessels [19,20,25]. Our in vitro experiments
demonstrate that activation of D2 dopamine receptors significantly
inhibited VEGF-induced expression of HoxD3 and its target genes
a5 and b1 integrins in endothelial cells. In contrast, pre-treatment
with eticlopride, abrogated this DA induced down-regulation of
both HoxD3 and its target integrins. These in vitro results also
correlated well and confirmed our in vivo results showing
eticlopride induced increased expression of HoxD3 and its target
integrins in wound tissues, thus indicating a novel association
between endogenous DA and wound angiogenesis. However,
angiogenesis in wound tissue is a complex process, involving
multiple growth factors and cytokines, therefore besides influenc-
ing HoxD3 expression, the possibility of involvement of DA
through its D2 receptors to interact with other growth factors and
their down stream pro-angiogenic target genes cannot be ruled
out.
Taken together, the information generated from the present
study thus has shown for the first time that in addition to
regulating pathological angiogenesis in tumors [5–6], DA through
its D2 receptors can also negatively influence physiological
angiogenesis in wounds and treatment with a specific D2
dopamine receptor antagonist can significantly increase wound
angiogenesis and thereby, expedite the process of wound tissue
repair. This novel information has immense translational value in
respect to better and efficient wound management by using D2 DA
receptor antagonists along with other conventional therapy for the
repair of damaged wound tissues.
Materials and Methods
Experimental wound model
All animal experiments were performed after approval by the
Institutional Animal Care and Use Committees. In the present
investigation, the experiments were carried out in full thickness
dermal wound bearing normal Swiss mice (4–6 weeks and
weighing 22–25 g). The animals were anesthetized with intraper-
itoneal (i.p.) injection of 100 ml solution containing ketamine and
xylazine mixture (2.215 and 0.175 mg, respectively; all from
Sigma, St. Louis). The dorsal hair of the mouse was shaved and
disinfected with an alcohol (70% ethanol) swab to prepare the back
skin for generation of a standardized full-thickness dermal wound.
Using an 8 mm dermal punch biopsy, two excisional wounds were
created at the same cranial-caudal level on the dorso-medial back
of each animal. At the end of the surgical procedure, cages were
placed on a heating pad until mice fully recovered from anesthesia
[33].
Treatment schedule with eticlopride, a specific D2 DA
receptor antagonist
After creation of wounds, the wound bearing mice were divided
into two equal groups. Immediately after wounding, mice of the
treatment group were given 10 mg/kg i.p. of eticlopride
hydrochloride (Sigma, USA) in 300 ml normal saline and
continued for four consecutive days with 24 hours interval [2].
The control group received similar volume of normal saline only.
Wound Healing Studies
Wound closure was documented with a digital camera. Time to
wound closure was defined as the time until the re-epithelialization
process was complete and the wound bed was filled with new
tissues. Wound area was measured by analyzing images using an
image analysis program (ImageJ, NIH) by tracing the wound
margin and calculating the pixel area. The pixel counts were then
related to a circular filter paper having the same diameter as the
original wound, which served as a reference for every wound
healing image assessment. The measurements were performed in
triplicate and mean values of consecutive tracings were computed
and expressed as percentage of closure from the original wound.
The percentage of wound closure was calculated as: (area of
original wound 2 area of actual wound) x 100/area of original
wound [33,34].
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expression
On day 5, after completion of eticlopride treatment for four
consecutive days, the extent of wound tissue neovascularization
and integrin expressions were examined in both vehicle treated
controls and eticlopride treated mice. Wound tissues from both the
groups were collected, washed in PBS and fixed in OCT
compound at 220uC for 1 hour and 5 mm cryostat sections were
cut from the mid-portion of the wounds with a cryomicrotome.
Sections were taken onto Poly-L-Lysine coated glass slides and
fixed in methanol at 220uC for 20 minutes and the slides were
stored at 280uC until assayed. The sections were stained with
anti-CD31 antibody (Goat anti-mouse IgG; R&D Systems, MN)
or anti-integrin a5b1 antibody (Rat anti-mouse IgG; Millipore,
MA) and biotin conjugated secondary antibodies (Rabbit anti-goat
IgG; Millipore, MA and Goat anti-rat; BD Pharmingen, CA) and
treated with ABC staining kit (Vector Laboratories, CA) and
Nova-Red substrate solution (Vector Laboratories, CA) to develop
color. Microvessel density (CD31 positive cells) in wound bed was
measured by counting the number of microvessels in 10 randomly
chosen high power microscopic fields within the sections [6].
For immunoblot analysis of HoxD3 in wound tissue, the entire
wound, as well as a ,2 mm margin of surrounding normal skin
were excised, cut into small pieces with the help of a clean sharp
razor blade, homogenized and the protein extracts from cells were
immunoprecipitated with anti-HoxD3 antibody (Santa Cruz, CA)
and immunoprecipitates were captured on protein A-agarose
beads. The immunocomplexes were then subjected to SDS-PAGE
and then transferred to polyvinyl difluoride membranes (Millipore,
MA) and immunoblotted. Goat anti-rabbit IgG HRP conjugated
(Santa Cruz, CA) was used as secondary antibody. Antibody
reactive bands were detected by enzyme - linked chemilumines-
cence (Pierce IL) [4].
Determination of D2 DA receptors in HUVEC by
immunoblotting and flow cytometry
HUVEC (human umbilical vein endothelial cells) (HUV-EC-C;
ATCC Number: CRL-1730) were cultured in ATCC formulated
F-12K Medium (Catalog No. 30-2004). To make the complete
growth medium, the following components were added to the base
medium: 0.1mg/ml heparin; 0.03–0.05 mg/ml endothelial cell
growth supplement (ECGS; Millipore, MA) & adjusted to a final
concentration of 10% fetal bovine serum. The presence of D2 DA
receptors in HUVEC were determined by both immunoblot and
flow cytometry analysis.
In vitro expanded HUVEC were lysed and the protein extracts
from cells were immunoprecipitated with mouse anti-D2 DA
receptor antibody (Santa Cruz, CA) and immunoprecipitates were
captured on protein A-agarose beads. Thereafter, the immuno-
complexes were subjected to SDS-PAGE and then transferred to
polyvinyl difluoride membranes (Millipore, MA) and immuno-
blotted. Goat anti-mouse IgG HRP conjugated (Santa Cruz, CA)
was used as secondary antibody. Antibody reactive bands were
detected by enzyme - linked chemiluminescence (Pierce, IL) [4].
Cultured HUVEC were further analyzed by flow cytometry
(FACS Calibur; BD Biosciences) to determine the presence of D2
DA receptors in these cells. HUVEC were incubated with mouse
anti-D2 DA receptor antibody, (Santa Cruz, CA). After incubation
with the primary antibody, FITC conjugated rat anti-mouse IgG
(eBioscience, CA) against the primary anti-D2 DA receptor
antibody was also added. Initial analysis gates were designed to
exclude dead cells and debris. Analyses were considered as
informative when adequate numbers of events (after acquisition of
10000 cells per sample) were collected in the gated cells.
Percentage of D2 DA receptor positive cells was finally determined
after comparing them with matched isotype controls [6].
Effects of DA on expressions of HoxD3 and its target
genes a5 and b1 integrins in HUVEC
To determine effect of DA receptor activation on HoxD3
expression in vitro, HUVEC were serum-starved for 24 hours and
then treated with 1 mM DA followed by addition of 10 ng/ml
VEGF (Millipore, MA) 5 minutes later. After incubation for
8 hours, cells were collected for protein isolation [2].
The protein extracts from cells of various experimental groups
were subjected to SDS-PAGE (non-reducing condition in case of
a5 integrin only) separately for each of these proteins and blotted
onto PVDF membranes (Millipore, MA). Primary antibody used
in western blots were rabbit anti-HoxD3 IgG (Santa Cruz, CA),
rabbit anti-Integrin a5 (Millipore, MA) and rabbit anti-Integrin b1
(Millipore, MA). Goat anti-rabbit IgG HRP conjugated (Santa
Cruz, CA) was used as secondary antibody for the western blots
[31].
Statistical analysis
Data are means of at least 6 different experiments 6 SEM.
Student’s t-test was used to analyze differences between groups. p
value ,0.05 was considered statistically significant [33,34].
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